Search clinical trials for: Obatoclax mesylate

Total 1655 results

European Organisation for Research and Treatment...

Terminated

Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate

Gastrointestinal Stromal Tumor

Italy
University of Colorado, Denver
University of Colorado Nutrition Obesity Research Center (NORC)

Active, not recruiting

MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women

Diastolic Dysfunction

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) (INV555)

Gastrointestinal Stromal Tumors

Saudi Arabia, Taiwan, Turkey, Egypt, Thailand, Russian Federation, South Africa, Lebanon, India, Tunisia, Algeria, Jordan
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma

Brain and Central Nervous System Tumors

United States
Teva Neuroscience, Inc.

Completed

A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease

Parkinson's Disease
Gemin X
Cephalon

Completed

A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Extensive-stage Small Cell Lung Cancer

Canada, United States, United Kingdom, Serbia, Bulgaria, India, Hungary, Czech Republic, Poland, Romania
Iman Al-Naggar, PhD
National Institute on Aging (NIA); American Urological Association; Urology Care... and other collaborators

Recruiting

Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome (Mito-LUTS)

Lower Urinary Tract Symptoms | Overactive Bladder Syndrome

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer

Recurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical Cancer

United States
Peking University Third Hospital
Beijing Hospital

Completed

Treatment of Mild Vascular Cognitive Impairment With Yangxue Qingnao Pill

Cerebrovascular Diseases

China
Baylor College of Medicine

Recruiting

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (TOKIN)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission | Chronic Myeloid Leukemia in Remission

United States
University of Aarhus

Completed

Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec (NSF)

Nephrogenic Systemic Fibrosis

Denmark
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

CML, Chronic Phase

China
University of California, San Francisco
Juvenile Diabetes Research Foundation

Completed

Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDM

United States, Australia
GlaxoSmithKline

Completed

A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects

Infections, Bacterial

United States
Technical University of Munich

Completed

Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

Germany, Austria
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Leukemia

United States
Medicines for Malaria Venture
Syneos Health; Nucleus Network Ltd

Completed

Study To Investigate The Relative Bioavailability of OZ439 Formulations In Healthy Volunteers

Healthy Volunteers

Australia
Novartis Pharmaceuticals

Terminated

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) (TOPS)

Leukemia, Myeloid, Chronic Phase

United States, Argentina, Italy, Canada, Australia, Brazil
Scandinavian Sarcoma Group

Completed

Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)

Sarcoma

Sweden
Goethe University

Recruiting

Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab (EWALL-BOLD)

B-Precursor ALL

Germany
Alvotech Swiss AG
Iqvia Pty Ltd

Completed

Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)

Psoriasis

Australia, New Zealand
Eisai Inc.

Completed

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

HER2-normal

United States
Eisai Korea Inc.

Completed

A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

Locally Advanced or Metastatic Breast Cancer

Korea, Republic of
Sarit Assouline
Novartis

Recruiting

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | Chronic Myeloid Leukemia, BCR/ABL-Positive

Canada
Goethe University

Completed

Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia

ALL, Recurrent, Adult

Germany
Beth Israel Deaconess Medical Center
Medical University of South Carolina; Johns Hopkins University; Massachusetts... and other collaborators

Completed

Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

Intracerebral Hemorrhage

United States, Canada
M.D. Anderson Cancer Center
BreakThrough Therapeutics

Completed

Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease

Chronic Myeloid Leukemia | Minimal Residual Disease

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Terminated

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

Myelogenous Leukemia, Chronic, Chronic Phase

United States
Brigham and Women's Hospital
National Heart, Lung, and Blood Institute (NHLBI); Baim Institute for Clinical...

Completed

Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA) (KIA)

Asthma

United States
M.D. Anderson Cancer Center
Abiogen Pharma

Terminated

TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients

Chronic Myelogenous Leukemia

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Leukemia

United States
Herbert Hurwitz
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

Uterine Carcinosarcoma | Recurrent Uterine Sarcoma

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Acral Lentiginous Malignant Melanoma

United States
National Cancer Institute (NCI)

Completed

A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer

Stage IV Gastric Cancer | Recurrent Gastric Cancer

United States
National Cancer Institute (NCI)

Completed

S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer

Breast Cancer
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer

United States
Oncology Specialists, S.C.

Completed

Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
M.D. Anderson Cancer Center
Novartis

Completed

Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST

Gastrointestinal Stromal Tumors

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Eisai Inc.

Completed

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Ewing Sarcoma | Non-rhabdomyosarcoma Soft Tissue Sarcoma | Relapsed/Refractory Rhabdomyosarcoma

United States
Taizhou EOC Pharma Co., Ltd.
Fountain Medical Development Co., Ltd.

Completed

Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors

Solid Tumor, Adult

China
Rigshospitalet, Denmark
Danish Research Centre for Magnetic Resonance

Unknown

The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis (EPO-ProgMS)

Multiple Sclerosis (Primary or Secondary Progressive Phase).

Denmark
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Metastatic Melanoma

Melanoma | Skin Neoplasms

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease (PD)

Parkinson's Disease
National Cancer Institute (NCI)

Completed

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Recurrent Neuroendocrine Carcinoma of the Skin | Stage III Neuroendocrine Carcinoma of the Skin | Stage II Neuroendocrine Carcinoma of the Skin

United States

Search clinical trials for: Obatoclax mesylate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations